Lyme disease vaccine candidate: Initiation of second study of Phase 2 clinical development
by Press Release from Outbreak News Today on (#4JAPS)
Biotech and vaccine development company, Valneva announced today the initiation of the second study of Phase 2 clinical development for its leading, unique Lyme disease vaccine candidate VLA15. The overall Phase 2 objectives for VLA15 are to determine the optimal dosage level and vaccination schedule for use in Phase 3 pivotal field efficacy studies, based ["]
The post Lyme disease vaccine candidate: Initiation of second study of Phase 2 clinical development appeared first on Outbreak News Today.